Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Buy” by Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has earned a consensus recommendation of “Buy” from the five brokerages that are currently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $41.25.

A number of research firms recently weighed in on ORKA. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Leerink Partners began coverage on shares of Oruka Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $44.00 target price for the company. Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a research note on Tuesday. TD Cowen assumed coverage on Oruka Therapeutics in a research note on Monday. They set a “buy” rating on the stock. Finally, Lifesci Capital began coverage on Oruka Therapeutics in a research report on Monday. They issued an “outperform” rating and a $41.00 price objective for the company.

Oruka Therapeutics Price Performance

ORKA stock opened at $26.47 on Wednesday. Oruka Therapeutics has a twelve month low of $18.72 and a twelve month high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.